CN103221032A - 药物组合物 - Google Patents

药物组合物 Download PDF

Info

Publication number
CN103221032A
CN103221032A CN201180054627XA CN201180054627A CN103221032A CN 103221032 A CN103221032 A CN 103221032A CN 201180054627X A CN201180054627X A CN 201180054627XA CN 201180054627 A CN201180054627 A CN 201180054627A CN 103221032 A CN103221032 A CN 103221032A
Authority
CN
China
Prior art keywords
compositions
rifaximin
ester
sodium
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201180054627XA
Other languages
English (en)
Chinese (zh)
Inventor
施里尼瓦斯·马杜卡尔·普拉恩达利
吉纳·麦赫特拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of CN103221032A publication Critical patent/CN103221032A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
    • G01N2013/006—Dissolution of tablets or the like
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201180054627XA 2010-09-13 2011-05-23 药物组合物 Pending CN103221032A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN2522/MUM/2010 2010-09-13
IN2522MU2010 2010-09-13
IN2539MU2010 2010-09-14
IN2539/MUM/2010 2010-09-14
PCT/GB2011/000785 WO2012035283A1 (en) 2010-09-13 2011-05-23 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
CN103221032A true CN103221032A (zh) 2013-07-24

Family

ID=44169144

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180054627XA Pending CN103221032A (zh) 2010-09-13 2011-05-23 药物组合物

Country Status (13)

Country Link
US (1) US20130315988A1 (enExample)
EP (1) EP2616044A1 (enExample)
JP (1) JP2013537182A (enExample)
KR (1) KR20140029356A (enExample)
CN (1) CN103221032A (enExample)
AU (1) AU2011303715A1 (enExample)
BR (1) BR112013005772A2 (enExample)
CA (1) CA2810598A1 (enExample)
MX (1) MX2013002802A (enExample)
NZ (1) NZ607935A (enExample)
RU (1) RU2013113752A (enExample)
WO (1) WO2012035283A1 (enExample)
ZA (1) ZA201301920B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110087688A (zh) * 2016-10-14 2019-08-02 希普拉有限公司 包含利福昔明的药物组合物

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
GB201306980D0 (en) * 2013-04-17 2013-05-29 Blueberry Therapeutics Ltd Methods
IN2014MU00916A (enExample) * 2014-03-20 2015-09-25 Cipla Ltd
KR102362719B1 (ko) 2014-05-12 2022-02-14 알파시그마 에스.피.에이. 리팍시민의 신규한 용매화 결정 형태, 생산물, 조성물 및 이의 용도
JP6867288B2 (ja) * 2014-07-21 2021-04-28 エーエムディー セラピューティックス エルエルシー リファマイシンの眼科用組成物およびその使用
EP3958841A1 (en) * 2019-04-22 2022-03-02 Mylan Specialty L.P. Meloxicam co-crystal compositions
WO2021260211A1 (en) * 2020-06-26 2021-12-30 Bausch Health Ireland Limited Targeted release rifaximin compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101036633A (zh) * 2007-04-28 2007-09-19 杭州民生药业集团有限公司 一种奥美拉唑肠溶微丸胶囊及其制备方法
CN101137350A (zh) * 2005-03-07 2008-03-05 意大利阿尔法韦士曼制药公司 包含利福昔明的胃稳定药物制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264494B1 (it) 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
IT1290679B1 (it) 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
US20070082870A1 (en) 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
WO2009008005A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
JP2009137922A (ja) * 2007-11-16 2009-06-25 Kaneka Corp リファマイシン誘導体を傷害組織にデリバリーする製剤
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
KR20110107806A (ko) 2008-12-10 2011-10-04 시플라 리미티드 리팍시민 복합체

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101137350A (zh) * 2005-03-07 2008-03-05 意大利阿尔法韦士曼制药公司 包含利福昔明的胃稳定药物制剂
CN101036633A (zh) * 2007-04-28 2007-09-19 杭州民生药业集团有限公司 一种奥美拉唑肠溶微丸胶囊及其制备方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110087688A (zh) * 2016-10-14 2019-08-02 希普拉有限公司 包含利福昔明的药物组合物
CN110087688B (zh) * 2016-10-14 2023-05-05 希普拉有限公司 包含利福昔明的药物组合物

Also Published As

Publication number Publication date
JP2013537182A (ja) 2013-09-30
ZA201301920B (en) 2013-10-30
EP2616044A1 (en) 2013-07-24
NZ607935A (en) 2015-01-30
KR20140029356A (ko) 2014-03-10
US20130315988A1 (en) 2013-11-28
BR112013005772A2 (pt) 2019-09-24
RU2013113752A (ru) 2014-10-20
WO2012035283A8 (en) 2013-08-22
MX2013002802A (es) 2013-06-03
AU2011303715A1 (en) 2013-04-04
WO2012035283A1 (en) 2012-03-22
CA2810598A1 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
CN103221032A (zh) 药物组合物
AU2011244783B2 (en) Pharmaceutical compositions
CN103209687A (zh) 包含地拉罗司的药物组合物
TWI696463B (zh) 阿比特龍乙酸錯合物，其製造方法及包含其的醫藥品組成物
JP2005531521A (ja) ドラッグ微粒子
CN101511343A (zh) 使用多元醇来获得利福昔明的稳定的多晶型形式
Moghaddam et al. Development of a nano–micro carrier system for sustained pulmonary delivery of clarithromycin
EP0862420A1 (en) Synthesis of drug nanoparticles by spray drying
CN102481281B (zh) 决奈达隆固体分散体及其制备方法
CN107320460B (zh) 一种尼罗替尼口服纳米制剂及其制备方法
CN108463213B (zh) 可吸入扎鲁司特颗粒的制备
CN111405900B (zh) 固体分散体
JP4875979B2 (ja) 難溶性薬物の微粒子分散液およびその製造方法
CN106999429B (zh) 纳米悬浮剂制剂
CN101961313B (zh) 一种伊曲康唑纳米结晶及其制备方法和应用
CN101780046A (zh) 一种伊曲康唑复合粉体及其制备方法
CN101554376B (zh) 一种高生物利用度的雷帕霉素组合物及制备方法
CN102327235B (zh) 一种头孢克肟脂质纳米粒固体制剂
CN110787125A (zh) 一种阿瑞匹坦纳米制剂及其制备方法
WO2013140120A1 (en) Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole
TWI520752B (zh) 決奈達隆固體分散體及其製備方法
Hashim et al. Isoniazid Active Pharmaceutical Ingredient in Nano Size Using Ultra Rapid Freezing
CN114222560A (zh) 介孔聚合物颗粒材料
Shelke et al. A review on solubility enhancement technique

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: Purandare Shrinivas Madhukar

Inventor after: Malhotra Geena

Inventor before: Purandare Shrinivas Madhukar

Inventor before: Malhorta Geena

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: PURANDARE SHRINIVAS MADHUKAR MAHOTRA GEENA TO: PURANDARE SHRINIVAS MADHUKAR MALHOTRA GEENA

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: India Mumbai PA rehl Ganbotelaao GA when Paimage Peninsula business park building Pula

Applicant after: Cipla Ltd.

Address before: Mumbai

Applicant before: Cipla Ltd.

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130724